Molecular targeted approaches in mantle cell lymphoma

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Mantle cell lymphoma (MCL) is a mature B-cell malignancy with a characteristic t(11;14) translocation.
• Despite initial chemotherapy response, most MCL patients relapse, leading to a median survival of 5-7 years.

Purpose of the Study:

• To review emerging targeted therapies for Mantle Cell Lymphoma.
• To highlight novel therapeutic strategies beyond conventional chemotherapy.

Main Methods:

• Literature review of recent advancements in MCL treatment.
• Analysis of targeted pathways including PI3K/AKT/mTOR, B-cell receptor signaling, and protein homeostasis.

Main Results:

• mTOR inhibitors (e.g., temsirolimus) and PI3K inhibitors (e.g., CAL-101) show clinical activity.
• BTK inhibitors (e.g., PCI-32765) demonstrate promise, suggesting a role for B-cell receptor signaling.
• Proteasome inhibitors (e.g., bortezomib) are effective in relapsed MCL, with ongoing development of second-generation agents and synergistic combinations (HDAC and HSP90 inhibitors).
• BH3 mimetics are emerging as sensitizers to chemotherapy.

Conclusions:

• Targeted therapies offer new hope for relapsed MCL patients.
• Combination strategies and novel drug classes are expanding treatment options.
• Clinical trial participation is crucial for advancing MCL treatment and patient outcomes.